FABP4 has also been associated with obesity and metabolic diseases, and is considered a promising therapeutic target for type 2 diabetes and atherosclerosis due to its roles in regulating metabolic and inflammatory pathways [9,10]. The gene discussed is FABP4; the disease is obesity due to melanocortin 4 receptor deficiency.